Valuation: FibroBiologics, Inc.

Market Cap 6.28M 5.71M 5.28M 4.77M 8.99M 590M 9.31M 63.44M 25.14M 317M 23.58M 23.08M 1B P/E 2026 *
-0.3x
P/E 2027 * -0.51x
Enterprise Value 6.28M 5.71M 5.28M 4.77M 8.99M 590M 9.31M 63.44M 25.14M 317M 23.58M 23.08M 1B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.26%
Yield 2026 *
-
Yield 2027 * -
Oct. 14 Fibrobiologics, Inc. Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs CI
Oct. 07 FibroBiologics, Inc. announced that it has received $1.02 million in funding from Peak One Investments, LLC CI
Oct. 07 FibroBiologics, Inc. Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside The Body CI
Oct. 06 FibroBiologics, Inc. announced that it expects to receive $1.02 million in funding from Peak One Investments, LLC CI
Sep. 22 RedChip Companies, Inc., FibroBiologics, Inc. - Special Call
Sep. 15 FibroBiologics, Inc. announced that it has received $0.500001 million in funding CI
Aug. 27 FibroBiologics, Inc. Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial CI
Aug. 24 Fibrobiologics, Inc. Announces Appointment of Leigh Steinberg to Board of Directors CI
Aug. 20 FibroBiologics, Inc. Announces Acceptance of Australian Patent Application for Cannabidiol Adjuvant Therapy for Treatment of Degenerative Disc Disease CI
Aug. 18 FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints CI
Jul. 31 FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Jul. 09 FibroBiologics, Inc. Announces Appointment of Kathleen 'Kate' Rubins to Board of Directors CI
Jul. 09 FibroBiologics, Inc. Announces the Resignation of Matt Link from the Board of Directors, Effective July 2, 2026 CI
1 day-2.56%
1 week-5.67%
Current month-2.86%
1 month-6.96%
3 months-14.77%
6 months-13.96%
Current year-79.92%
1 week 0.89
Extreme 0.89
1.04
1 month 0.88
Extreme 0.8812
1.24
Current year 0.62
Extreme 0.62005
9.6
1 year 0.62
Extreme 0.62005
9.6
3 years 0.62
Extreme 0.62005
1,100
5 years 0.62
Extreme 0.62005
1,100
10 years 0.62
Extreme 0.62005
1,100
Manager TitleAgeSince
Chief Executive Officer 62 2021-04-07
Director of Finance/CFO 53 2025-06-08
Chief Tech/Sci/R&D Officer 57 2021-07-31
Director TitleAgeSince
Director/Board Member 60 2021-04-07
Director/Board Member 64 2021-04-07
Director/Board Member - 2026-08-19
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Chief Technology Officer

597,016 8.9666%
7/8/26 Other

Director

562 0.0108%
5/4/26 Free

Chief Executive Officer

92,410 2.6306%
Change 5-day change 1-year change 3-year change Capi.($)
-2.56%-5.67%-87.72% - 6.28M
-1.29%-3.91%+51.98%+69.06% 65.56B
-1.55%-0.02%+9.04%+91.02% 60.41B
-0.21%+1.27%+24.10%+88.56% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
+0.10%-1.23%+79.04%+59.54% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -0.85%-2.04%+23.36%+176.57% 40B
Weighted average by Cap. -0.79%-1.58%+35.06%+150.63%

Financials

2026 *2027 *
Net sales - -
Net income -18.51M -16.81M -15.54M -14.03M -26.48M -1.74B -27.41M -187M -74.03M -933M -69.45M -67.98M -2.95B -22.96M -20.86M -19.27M -17.41M -32.85M -2.16B -34M -232M -91.82M -1.16B -86.15M -84.32M -3.66B
Net Debt - -
Projected Income Statement - Annual - FibroBiologics, Inc.
Logo FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 270+ United States and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. Its advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. It has completed its IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing. CYPS317 is its allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. It is developing CYMS101 as an intravenously administered allogeneic fibroblast single cell, and fibroblast spheroid, cell-based therapy to treat multiple sclerosis (MS).
Employees
-
Date Price Change Volume
26-11-16 $0.9034 -2.56% 97,613
26-11-13 $0.9271 -4.21% 35,563
26-11-12 $0.9678 -2.81% 64,515
26-11-11 $0.9958 +7.78% 54,376
26-11-10 $0.9239 -3.53% 59,677
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - FibroBiologics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.9034USD
Average target price
12.50USD
Spread / Average Target
+1,283.66%
  1. Stock Market
  2. Stocks
  3. FBLG Stock